Search research articles
Contact Us
Filters
Showing results (21-30 of 30) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 30 results.
Journal of Medicinal Chemistry
|
August 1, 1987
Inhibitors of dopamine beta-hydroxylase. 3. Some 1-(pyridylmethyl)imidazole-2-thiones
S T Ross, L I Kruse, E H Ohlstein, et al.
Journal of Medicinal Chemistry
|
February 1, 1990
Some benzyl-substituted imidazoles, triazoles, tetrazoles, pyridinethiones, and structural relatives as multisubstrate inhibitors of dopamine beta-hydroxylase. 4. Structure-activity relationships at the copper binding site
L I Kruse, C Kaiser, W E DeWolf, et al.
Journal of Medicinal Chemistry
|
March 1, 1987
Multisubstrate inhibitors of dopamine beta-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site
L I Kruse, C Kaiser, W E DeWolf, et al.
Journal of Medicinal Chemistry
|
June 1, 1986
Syntheses and in vitro evaluation of 4-(2-aminoethyl)-2(3H)-indolones and related compounds as peripheral prejunctional dopamine receptor agonists
R M DeMarinis, G Gallagher, R F Hall, et al.
Journal of Medicinal Chemistry
|
September 1, 1980
6-(Phenylthio)-substituted 2,3,4,5-tetrahydro-1H-3-benzazepines, a novel class of dopamine receptor antagonists and neuroleptics
C Kaiser, F E Ali, W E Bondinell, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 19, 1999
Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis
M W Lark, G B Stroup, S M Hwang, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 5, 1999
Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonists
R M Keenan, W H Miller, M A Lago, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 5, 1999
Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis model
R M Keenan, M A Lago, W H Miller, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 16, 1999
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model
W H Miller, W E Bondinell, R D Cousins, et al.
Journal of Medicinal Chemistry
|
January 14, 2000
Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic
W H Miller, D P Alberts, P K Bhatnagar, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 30) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 30 results.
Journal of Medicinal Chemistry
|
August 1, 1987
Inhibitors of dopamine beta-hydroxylase. 3. Some 1-(pyridylmethyl)imidazole-2-thiones
S T Ross, L I Kruse, E H Ohlstein, et al.
Journal of Medicinal Chemistry
|
February 1, 1990
Some benzyl-substituted imidazoles, triazoles, tetrazoles, pyridinethiones, and structural relatives as multisubstrate inhibitors of dopamine beta-hydroxylase. 4. Structure-activity relationships at the copper binding site
L I Kruse, C Kaiser, W E DeWolf, et al.
Journal of Medicinal Chemistry
|
March 1, 1987
Multisubstrate inhibitors of dopamine beta-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site
L I Kruse, C Kaiser, W E DeWolf, et al.
Journal of Medicinal Chemistry
|
June 1, 1986
Syntheses and in vitro evaluation of 4-(2-aminoethyl)-2(3H)-indolones and related compounds as peripheral prejunctional dopamine receptor agonists
R M DeMarinis, G Gallagher, R F Hall, et al.
Journal of Medicinal Chemistry
|
September 1, 1980
6-(Phenylthio)-substituted 2,3,4,5-tetrahydro-1H-3-benzazepines, a novel class of dopamine receptor antagonists and neuroleptics
C Kaiser, F E Ali, W E Bondinell, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 19, 1999
Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis
M W Lark, G B Stroup, S M Hwang, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 5, 1999
Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonists
R M Keenan, W H Miller, M A Lago, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 5, 1999
Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis model
R M Keenan, M A Lago, W H Miller, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 16, 1999
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model
W H Miller, W E Bondinell, R D Cousins, et al.
Journal of Medicinal Chemistry
|
January 14, 2000
Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic
W H Miller, D P Alberts, P K Bhatnagar, et al.
Page
of 3